Mobia Medical MOBI 深 沪
已收盘 09-25 16:00:00 美东时间
9.06
+0.250
+2.84%
华盛通- 最 高9.32
- 今 开8.78
- 成交量 15.66万股
- 最 低 8.78
- 昨 收 8.81
- 总市值 3.02亿
- 52周最高 15.29
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.13
- 委 比 9.09%
- 总股本 3329.11万
- 历史最高 15.29
- 量 比 0.30
- 振 幅 6.13%
- 历史最低 2.13
- 每 手 1
- 风险率 1.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Gap Posts Upbeat Q2 Earnings, Joins Solstice Advanced Materials, N-Able And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Nasdaq Composite falling around 0.1% on Friday. Shares of Gap Inc (NYSE:GAP) rose sharply as the company reported better-than-expected second-quarter earnings and raised their FY26 EPS guidance above estimates. Revenue came in at $3.65 billion, versus estimates of $3...
08-28 22:22
Mobia Medical Announces Addition of Paired VNS to Updated AHA Stroke Guidelines
Mobia Medical's Vivistim® Paired VNS™ System has been recognized in the 2026 American Heart Association and American Stroke Association guideline as a treatment option to improve upper-limb function in chronic stroke survivors. The guideline highlights the use of vagus nerve stimulation paired with high-dose task-specific training. Mobia Medical's system is the only FDA-approved solution for this approach. The recognition validates the technology...
08-28 11:30
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
BTIG Reiterates Buy on Mobia Medical, Maintains $19 Price Target
BTIG analyst Ryan Zimmerman reiterates Mobia Medical (NASDAQ:MOBI) with a Buy and maintains $19 price target.
08-12 17:56
Mobia Medical Sees FY2026 Sales $54.000M-$56.000M vs $53.504M Est
Mobia Medical (NASDAQ:MOBI) sees FY2026 sales of $54.000 million-$56.000 million vs $53.504 million analyst estimate.
08-12 04:31
Mobia Medical Q2 EPS $(1.10) Misses $(0.82) Estimate, Sales $13.505M Beat $12.380M Estimate
Mobia Medical (NASDAQ:MOBI) reported quarterly losses of $(1.10) per share which missed the analyst consensus estimate of $(0.82) by 34.15 percent. The company reported quarterly sales of $13.505 million which beat the analyst consensus estimate of $12.380 million by 9.09 percent.
08-12 04:08
Mobia Medical Reports Second Quarter 2026 Financial Results
Mobia Medical reported strong second-quarter 2026 results with 102% revenue growth to $13.5 million, driven by higher adoption of its Vivistim System. Gross margin improved to 83.2%, and the company completed its IPO, raising $134 million. It also published positive clinical data and appointed new board members. Despite a net loss of $21 million, cash reserves increased to $177 million, supporting its growth strategy. The company expects full-yea...
08-11 20:05
Mobia Medical Appoints Myriam Curet, M.D., to its Board of Directors
Mobia Medical, Inc. announced the appointment of Myriam Curet, M.D., as an independent director on its Board of Directors. Dr. Curet brings extensive clinical and executive experience, particularly in medical technology and corporate governance, which will support Mobia's growth and expansion of its Vivistim® Paired VNS™ System for stroke recovery. Her expertise in translating scientific advancements into clinical impact will be instrumental in e...
08-03 20:05
Mobia Medical Appoints Reza Zadno, Ph.D., to its Board of Directors
Mobia Medical, Inc. has appointed Reza Zadno, Ph.D., as an independent director and member of the Compensation Committee. Dr. Zadno, with over 35 years of medical technology experience, has a track record of leading companies through IPOs and commercial expansion. He currently serves as an Operating Partner at Jolt Capital and a Special Advisor to the American Academy of Ophthalmology. Mobia Medical specializes in stroke recovery solutions, inclu...
07-15 20:05
Mobia Medical Announces Publication Of 2-Yr Follow-Up Data From VNS-REHAB Study In Neurology, Official Peer-Reviewed Journal Of American Academy Of Neurology
Mobia Medical, Inc. (NASDAQ:MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced the publication of two-year follow-up data from the VNS-REHAB study in Neurology®, the official peer-reviewed journal of ...
07-15 04:20
